Reduction seen in risk for clinically important kidney outcomes and death from cardiovascular causes<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, May 31, 2024 (HealthDay News) — For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from cardiovascular causes, according to a study published online May 24 in the New England Journal of Medicine <\/em>to coincide with the annual European Renal Association Congress, held from May 23 to 26 in Stockholm.<\/p>\n Vlado Perkovic, M.B., B.S., Ph.D., from the University of New South Wales in Sydney, and colleagues randomly assigned patients with type 2 diabetes and chronic kidney disease to receive subcutaneous semaglutide (1.0 mg weekly) or placebo (1,767 and 1,766 participants, respectively).<\/p>\n Participants were followed for a median of 3.4 years after recommendation of early trial cessation at a prespecified interim analysis. The researchers found that the risk for a primary outcome event (major kidney disease events, a composite of the onset of kidney failure, at least a 50 percent reduction in the estimated glomerular filtration rate from baseline, or death from kidney-related or cardiovascular causes) was significantly lower in the semaglutide group (331 versus 410 first events; hazard ratio, 0.76). Similar results were seen for a composite of the kidney-specific components of the primary outcome and for death from cardiovascular causes (hazard ratios, 0.79 and 0.71, respectively). All confirmatory secondary outcomes favored semaglutide.<\/p>\n “These benefits reflect important clinical effects on kidney, cardiovascular, and survival outcomes among high-risk patients, particularly given the reassuring safety findings, and support a therapeutic role for semaglutide in this population,” the authors write.<\/p>\n Several authors disclosed ties to biopharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n